Seeding Neuritic Plaques from the Distance: A Possible Role for Brainstem Neurons in the Development of Alzheimer’s Disease Pathology

Zoia Muresan  Virgil Muresan
Department of Pharmacology and Physiology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, N.J., USA

Aβ oligomers that triggers further aggregation of extracellular proteins. **Conclusion:** We propose that brainstem neurons, known to send projections throughout the brain, could provide the ‘bad seed’ of Aβ that nucleates plaques in the cerebral cortex and hippocampus of AD brains.

**Background and Objective**

Alzheimer’s disease (AD), a complex neurodegenerative disorder, is characterized by two major lesions: the neuritic plaques and the neurofibrillary tangles. Neuritic plaques contain extracellular deposits of Aβ-amyloid (Aβ) peptide, a metabolite of the transmembrane protein, Aβ-amyloid precursor protein [1].

A characteristic feature of AD neuropathology is the preferential formation of plaques in cortical and hippocampal brain regions. Yet, the initial events that trigger plaque formation in certain brain regions and not in others are not known. According to the seeded polymerization theory [2], the aggregation of soluble Aβ, which leads to plaque formation, is nucleated by ‘bad seeds’ of oligomeric Aβ. The origin and nature of these hypothetical seeds are not known. As described below, our work with the neuronal cell line CAD suggests that Aβ oligomers form at the terminals of projections of brainstem neurons and could act as such seeds.
Methods

CAD cells [a locus coeruleus (LC)-derived cell line] [3] have emerged as an important in vitro experimental system for studying the molecular pathobiology of AD [4–8], and – as highlighted here – may be particularly relevant to the initiation of neuritic plaque formation. Using immunocytochemical and biochemical approaches, we have characterized the CAD cell line with respect to the metabolism of Aβ precursor protein and generation of Aβ.

Results

We discovered that CAD cells are prone to accumulation of large amounts of intracellular Aβ at the terminals of their processes (fig. 1), similar to what may occur in brain neurons, during the initial phases of AD [7]. Using carboxy-terminal-end antibodies to Aβ species, we showed that these Aβ accumulations contain both the Aβ40 and Aβ42 peptides [7]. Cross-reactivity of the accumulations with an antioligomer antibody that preferentially detects species larger than the octamer (A11) [9] indicated that the accumulations include large-molecular-size Aβ oligomers [7].

The neuritic accumulation of Aβ in CAD cells is restricted to a small population of cells that show redistribution of β-secretase (BACE1) to the processes, where it colocalizes with Aβ and markers of late endosomes and autophagic vacuoles [7]. These findings suggest that the Aβ accumulations could be generated through endocytosis or macroautophagy, two processes previously implicated in the formation of the neuritically localized Aβ [10, 11]. Importantly, unlike the LC-derived CAD cells, cultured cortical and hippocampal neurons do not show detectable Aβ accumulations at their neuritic terminals (data not shown).

Here, we hypothesize that in AD brains, accumulations of Aβ similar to those observed in CAD cells (fig. 1) could form at the projection terminals of brainstem neurons (which send projections throughout the central nervous system, including the cerebral cortex and hippocampus), and serve as seeds for further Aβ aggregation. This process leads to plaque formation at locations remote from the brainstem, such as the cerebral cortex and hippocampus (fig. 2). The LC is largely affected by cell death early in AD. However, since this brain region mostly lacks neuritic plaques, the prevailing view was that neuronal loss in the LC is caused by the cortical Aβ, which ‘poisons’ the projections of brainstem cells [13]. By contrast, our results suggest that the neuropathology of AD may actually begin in the subcortical regions, and then spread to the cortex and hippocampus. This is in line with earlier reports suggesting that, in AD, pathologic alterations in the LC may spread to cortical and hippocampal brain regions [14–16].

How could the intracellular Aβ accumulations (fig. 1) become extracellular and serve as seeds for Aβ deposition? The mechanism could be the fusion of the Aβ-containing autophagosomes and late endosomes with the plasma membrane, or alternatively, neurite degeneration. Indeed, we occasionally found neuritic debris containing Aβ, in the areas enriched in CAD cells having Aβ accumulations (fig. 3). A further question raised by this result is what could trigger neurite degeneration in these cells? We found that, while the anterograde transport of small vesicles is not significantly affected [7], the transport and the neuritic localization of mitochondria is evidently perturbed in CAD cells that contain Aβ accumulations.

Fig. 1. CAD cells immunolabeled with antibody 6E10 (Signet, Dedham, Mass., USA), showing Aβ accumulations at neurite endings (A). B An enlargement of a process, showing localization of Aβ to large particles resembling late endosomes and autophagosomes.

Fig. 2. Diagram showing plaques (*) at the terminals of projections of brainstem (BS) neurons. The drawing was modified from Aston-Jones and Cohen [12], and used with permission from the Annual Review of Neuroscience, vol. 28, 2005, by Annual Reviews (www.annualreviews.org).
(fig. 4). This could result in diminished supply of ATP in the neurites, which could cause their observed degeneration.

**Conclusions**

Taken together, our results point to the brainstem neurons as possible initiators of plaque formation in AD. We propose that the initial seeds of aggregated Aβ are produced at the neurite terminals of the brainstem neurons that project into the brain regions prone to AD pathology (e.g. cerebral cortex, hippocampus). These seeds then trigger further aggregation of soluble, extracellular Aβ into plaques. Thus, our work offers a novel perspective on AD pathogenesis. In addition, the CAD cell system that we established is ideally suited for screening of compounds that could prevent accumulation of Aβ, and thus could be used to treat brainstem neurons at the early stages of AD.

**Acknowledgments**

This work was supported by National Institutes of Health grant 5R01GM068596 and funds from UMDNJ-NJMS. The work was started at Case Western Reserve University, Cleveland, Ohio, USA.

**References**


